Inspire Medical Systems Business Summary

Inspire Medical Systems, Inc. (INSP) operates as a medical technology leader specializing in the development and commercialization of minimally invasive neurostimulation solutions for obstructive sleep apnea (OSA). The company generates the vast majority of its revenue through the direct sale of its proprietary Inspire system—an FDA-approved, surgically implanted device—to hospitals and ambulatory surgery centers, primarily in the United States. Its business is segmented into U.S. and International operations, with growth currently driven by the 2025 commercial launch of the Inspire V system and expansion into existing and new medical centers. In the competitive landscape, Inspire faces direct pressure from Nyxoah in the neurostimulation space, as well as indirect competition from established OSA treatment providers such as ResMed (CPAP) and SomnoMed (oral appliances). Inspire maintains a dominant market position as the premier alternative for patients who are unable to tolerate or fail traditional CPAP therapy, though it is currently navigating 2026 reimbursement headwinds following a coding clarification for its latest device. The company was founded in 2007 as a spin-off from Medtronic, inheriting a robust portfolio of neurostimulation intellectual property. Leadership is anchored by Founder, President, and CEO Timothy P. Herbert, who brings over 30 years of medical device experience, including an 11-year tenure at Medtronic in product development and clinical research. The executive team was recently strengthened by the appointment of Matt Osberg as Chief Financial Officer in January 2026, formerly of Apogee Enterprises, and includes John C. Rondoni as Chief Product & Innovation Officer. Inspire’s Board of Directors features high-profile industry veterans, including Casey M. Tansey of U.S. Venture Partners and Dr. Myriam J. Curet, the Chief Medical Officer of Intuitive Surgical, reflecting a deep pedigree in surgical robotics and venture-backed healthcare scaling.